JournalsHub
.online
Find My Journal
NV

Nicholas J. Vogelzang

Comprehensive Cancer Centers of Nevada US

ORCID iD 0000-0002-7665-6079
1,129
Publications
69,212
Citations
115
H-Index
511
i10-Index
3.0
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma OA
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee +15 more
New England Journal of Medicine 2017
3,367
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Chris Parker, Sten Nilsson, Daniel Heinrich, Svein Inge Helle, Joe M. O’Sullivan +25 more
New England Journal of Medicine 2013
3,313
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Claude Denham, E. Kaukel +7 more
Journal of Clinical Oncology 2003
3,054
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer OA
Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard +12 more
New England Journal of Medicine 2015
2,798
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer OA
H. Barton Grossman, Ronald B. Natale, Catherine M. Tangen, V. O. Speights, Nicholas J. Vogelzang +6 more
New England Journal of Medicine 2003
2,625

Publications

1,127 total

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial PDF

Matthew D. Galsky, Jóse Ángel Arranz Arija, Aristotelis Bamias, Ian D. Davis, Maria De Santis et al. - The Lancet, 2020
Cited by 780 OpenAlex

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial PDF

Christos E. Kyriakopoulos, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard et al. - Journal of Clinical Oncology, 2018
Cited by 1,096 OpenAlex

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma PDF

Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee et al. - New England Journal of Medicine, 2017
Cited by 3,367 OpenAlex

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial PDF

Thomas Powles, Ignacio Durán, Michiel S. van der Heijden, Yohann Loriot, Nicholas J. Vogelzang et al. - The Lancet, 2017
Cited by 1,406 OpenAlex

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

Thomas Powles, Peter H. O’Donnell, Christophe Massard, Hendrik-Tobias Arkenau, Terence W. Friedlander et al. - JAMA Oncology, 2017
Cited by 845 OpenAlex

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer PDF

Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard et al. - New England Journal of Medicine, 2015
Cited by 2,798 OpenAlex

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Thomas Powles, Joseph P. Eder, Gregg Fine, Fadi S. Braiteh, Yohann Loriot et al. - Nature, 2014
Cited by 2,416 OpenAlex

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Chris Parker, Sten Nilsson, Daniel Heinrich, Svein Inge Helle, Joe M. O’Sullivan et al. - New England Journal of Medicine, 2013
Cited by 3,313 OpenAlex

Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.

Anthony Mega, D. Petrylak, P. Kantoff, Joe Stephenson, Nicholas J. Vogelzang - Unknown Venue, 2013
Cited by 7 Semantic Scholar

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Karim Fizazi, Howard I. Scher, Arturo Molina, Christopher J. Logothetis, Kim N. et al. - The Lancet Oncology, 2012
Cited by 1,378 OpenAlex

Research Topics

Prostate Cancer Treatment and Research (375) Renal cell carcinoma treatment (162) Radiopharmaceutical Chemistry and Applications (149) Bladder and Urothelial Cancer Treatments (148) Cancer Immunotherapy and Biomarkers (131)

Frequent Co-Authors

NO
Noah M. Hahn
3 joint publications
JO
Joel Picus
3 joint publications
JO
Joaquim Bellmunt
2 joint publications
JA
Jae‐Lyun Lee
2 joint publications
DA
Daniel P. Petrylak
2 joint publications
CO
Cora N. Sternberg
2 joint publications

Affiliations

Université Paris-Sud
FR 2016 - 2016
Northwestern University
US 1995 - 1995
Trinity Christian College
US 1973 - 1973
San Antonio College
US 2013 - 2013
University of Southern California
US 2012 - 2010

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now